Gilead Sciences, Inc. vs Riot Platforms Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Riot Platforms Inc trades at $16.89 (market cap $6.32B). The key difference: Gilead Sciences, Inc. is far larger — about 28.9× Riot Platforms Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Riot Platforms Inc for 16 Days on average.
| GILD | RIOT | |
|---|---|---|
Market Cap | $182.40B | $6.32B |
Volume | 4,469,821 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $155.80 | $28.67 |
52-Week Low | $117.18 | $11.83 |
Typical Hold Time | 111 Days | 16 Days |
Enterprise Value | $205.46B | $6.73B |
Dividend Yield | 2.23% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
RIOT stock trades at $16.84, down 9.17% in the past 24 hours amid bearish technical signals. The company shows concerning fundamentals with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. However, analyst sentiment remains overwhelmingly positive with 18 buy ratings and a consensus price target of $31.64, representing 88% upside potential. Recent strategic shifts toward AI data center operations with $9.8 billion in contracted lease revenue through 2048 provide long-term growth catalysts.
The outlook remains polarized between strong analyst optimism and challenging financial performance. Investment opportunity exists in RIOT's strategic pivot to AI infrastructure with secured long-term revenue streams, but substantial execution risks persist given current profitability challenges and negative cash flow generation. Stock investors face volatility from both Bitcoin price sensitivity and the company's transition to new business models.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →